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Abstract:  
A simple, Accurate, precise method was developed for the simultaneous estimation of the Mupirocin and 
Fluticasone in ointment dosage form by reverse phase high performance liquid chromatography. 
Chromatogram was run through Standard Discovery 250 x 4.6 mm, 5. Mobile phase containing Buffer Ortho 
phosphoric acid: Acetonitrile taken in the ratio 55:45 was pumped through column at a flow rate of 1ml/min. 
Buffer used in this method was 0.1% Perchloric acid buffer. Temperature was maintained at 30°C. Optimized 
wavelength selected was 230nm. Retention time of Mupirocin and Fluticasone were found to be 2.146 min and 
2.770 min. percentage relative standard deviation of the Mupirocin and Fluticasone were and found to be 0.4 
and 0.5 respectively. Percentage Recovery was obtained as 98.75% and 99.42% for Mupirocin and Fluticasone 
respectively. Limit of detection, Limit of quantitation values obtained from regression equations of Mupirocin 
and Fluticasone were 0.38, 1.16 and 0.02, 0.05 respectively. Regression equation of Mupirocin is y = 10256.x + 
82433, and y= 24529x + 3330 of Fluticasone. Retention times were decreased and run time was decreased, so 
the method developed was simple and economical that can be adopted in regular Quality control test in 
Industries. 
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INTRODUCTION: 
Analytical methods are used for product research, 
product development, process control and chemical 
quality control purposes. Each of the techniques 
used in chromatographic or spectroscopic, have 
their own special features and deficiencies, which 
must be considered. Each step in the method must 
be investigated to determine the extent to which 
environment, matrix, or procedural variables can 
affect the estimation of analyte in the matrix from 
the time of collection up to the time of analysis. 
Pharmaceutical analysis require very precise and 
accurate assay methods to quantify drugs either in 
Pharmaceutical or biological samples. The assay 
methods have to be sensitive, selective, rugged and 
reproducible. Analytical chemistry is the qualitative 
and quantitative analysis of drug substances in 
biological fluids (mainly plasma and urine) or 
tissue [1-4]. It plays a significant role in the 
evaluation and interpretation of pharmacokinetic 
data. The main analytical phase comprises method 
development, method validation and sample 
analysis (method application).  
Aim: 
The main aim of the present study is to develop an 
accurate, precise, sensitive, selective, reproducible 
and rapid analytical technique for simultaneous 
estimation of Mupirocin, Fluticasone in bulk and 
ointment dosage form. The scope for developing 
and validating an analytical method is to ensure a 
suitable method for a particular analyte. The main 
objective was of the present study to improve the 
analytical conditions for the separation of active 
ingredient from formulation which could be done 
in the development and validation. 
 
Objective: 
Literature survey reveals that there are only a few 
methods reported so far in the determination of 
Mupirocin and Fluticasone in markets formulation 
.Moreover, there is also lack of adequate 
information regarding stability indicating studies 
on method developed earlier for the estimation of 
Mupirocin and Fluticasone in pharmaceutical 
formulation. So there is need for the development 
of new method for estimation of Mupirocin and 
Fluticasone formulation available in market, along 
with its stability studies in order to determine the 
degradation products as well as possible pathway 
of degradation. 
Following are the objectives of the present work:  
 To develop a new stability indicating High 
performance liquid chromatography (HPLC) 
method for simultaneous estimation of 
Mupirocin and Fluticasone. 
 Performing accelerated stability testing for the 
drug substances as per International 
Conference on Harmonization (ICH) 
guidelines. 
 Analytical method validation 
 To apply the validated method for the 
simultaneous estimation of Mupirocin and 
Fluticasone in pharmaceutical formulation. 
MATERIALS AND METHODS: 
Materials:  
Mupirocin and Fluticasone pure drugs (API), 
Combination Mupirocin and Fluticasone tablets 
(Flutibact ), Distilled water, Acetonitrile, 
Phosphate buffer, , Methanol, Potassium 
dihydrogen  ortho phosphate buffer,  Ortho-
phosphoric acid. All the above chemicals and 
solvents are from Rankem. 
Instruments: 
Electronics Balance-Denver, pH meter -BVK 
enterprises, India, Ultrasonicator-BVK enterprises, 
WATERS HPLC 2695 SYSTEM equipped with 
quaternary pumps, Photo Diode Array detector and 
Auto sampler integrated with Empower 2 Software, 
Ultra violet-Visible (UV-VIS) spectrophotometer 
PG Instruments T60 with special bandwidth of 2 
mm and 10mm and matched quartz cells integrated 
with UV win 6 Software was used for measuring 
absorbances of Mupirocin and Fluticasone 
solutions. 
Methods: 
Optimisation of chromatographic conditions 
 Selection of wavelength 
From the UV-visible spectophotometric 
results, a detection wavelength of 230nm 
was selected . Because at this wavelength 
they showed maximum absorbance with 
good peak intensity, good peak shape and 
height was observed. 
 
Fig 1: Individual UV spectra of Mupirocin and 
Fluticasone 
λmax of Mupirocin  and Fluticasone was 274.4nm 
and 246.0nm respectively. 
Overlay spectra gave the optimized wavelength for 
these two drugs. 
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Fig 2: Overlay UV spectra of Mupirocin and 
Fluticasone 
Optimized wavelength selected was 230nm. 
 
Preparation of Solutions: 
Diluent: Based up on the solubility of the drugs, 
diluent was selected, Acetonitrile and Water taken 
in the ratio of 50:50 
Preparation of Standard stock solutions: 
Accurately weighed 30mg of Mupirocin, 5mg of 
Fluticasone and transferred to 10ml and 100ml 
individual volumetric flasks and 3/4 th of diluents 
was added to these flask and sonicated for 10 
minutes. Flask were made up with diluents and 
labeled as Standard stock solution. ( 3000µg/ml of 
Mupirocin and 50µg/ml fluticasone) 
Preparation of Standard working solutions 
(100% solution): 1ml from each stock solution 
was pipetted out and taken into a 10ml volumetric 
flask and made up with diluent. (300µg/ml of 
mupirocin and 5µg/ml of Fluticasone) 
 
Preparation of buffer: 
0.1%OPA Buffer: 1ml of ortho phosphoric acid 
was diluted to 1000ml with HPLC grade water. 
 
Degradation Studies: 
Oxidation: 
To 1 ml of stock solution of Mupirocin and 
Fluticasone, 1 ml of 20% hydrogen peroxide 
(H2O2) was added separately. The solutions were 
kept for 30 min at 600c. For HPLC study, the 
resultant solution was diluted to obtain 
300µg/ml&5µg/ml solution and 10 µl were 
injected into the system and the chromatograms 
were recorded to assess the stability of sample. 
 
Acid Degradation Studies: 
To 1  ml of stock  solution Mupirocin and 
Fluticasone, 1 ml of 2N Hydrochloric acid was 
added and refluxed for  30mins at 600c .The 
resultant solution was diluted to obtain 
300µg/ml&5µg/ml solution and 10 µl solutions 
were injected into the system and the 
chromatograms were recorded to assess the 
stability of sample. 
 
Alkali Degradation Studies: 
To 1 ml of stock solution Mupirocin and 
Fluticasone, 1 ml of 2N sodium hydroxide was 
added and refluxed for 30mins at 600c. The 
resultant solution was diluted to obtain 
300µg/ml& 5µg/ml solution and 10 µl were               
injected into the system and the chromatograms 
were recorded to assess the stability of sample. 
 
Dry Heat Degradation 
Studies: 
The standard drug solution wa s  placed in oven at 
105°C for 1 h to study dry heat degradation. For 
HPLC study, the resultant solution was diluted to 
300µg/ml & 5µg/ml solution and10µl were 
injected into the system and the chromatograms 
were recorded to assess the stability of the 
sample. 
 
Photo Stability Studies: 
The photochemical stability of the drug was also 
studied by exposing the 2000µg/ml & Fluticasone 
µg/ml solution to UV Light by keeping the beaker in 
UV Chamber for 1days or 200 Watt hours/m2 in 
photo stability chamber. For HPLC study, the 
resultant solution was diluted to obtain 300µg/ml& 
5µg/ml solutions and 10 µl were injected into the 
system and the chromatograms were recorded to 
assess the stability of sample. 
 
Neutral Degradation Studies:  
Stress testing under neutral conditions was studied 
by refluxing the drug in water for 1h r s  at a 
temperature of 60º. For HPLC study, the resultant 
solution was diluted to 300µg/ml& 5µg/ml 
solution and 10 µl were injected into the system 
and the chromatograms were recorded to assess 
the stability of the sample. 
 
RESULTS AND DISCUSSION: 
Method Development: 
Proper selection of the method depends upon the 
nature of the sample (ionic or ionizable or neutral 
molecule), its molecular weight and solubility. 
Mupirocin and Fluticasone were dissolved in 
solvents, so the developed method of estimation 
was carried out on reverse phase high performance 
liquid chromatography. To develop a rugged and 
suitable HPLC method for the quantitative 
determination of Mupirocin and Fluticasone the 
analytical conditions were selected after the 
consideration of different parameters such as 
diluent, buffer, buffer concentration, organic 
solvent for mobile phase and mobile phase 
composition, and other chromatographic 
conditions. Preliminary trials were taken with 
different composition of buffer and organic phase 
of mobile phases . The column selection has been 
done by backpressure, resolution, peak shape, 
theoretical plates and day-to-day reproducibility of 
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the retention time and resolution between 
Mupirocin and Fluticasone peaks. After evaluating 
all these factors, a Standard Discovery column was 
found to be giving satisfactory results. The 
selection of acetonitrile and buffer were based on 
chemical structure of both the drugs. The acidic pH 
range was found suitable for solubility, resolution, 
stability, theoretical plates, and peak shape of both 
components. Best results were obtained with 50% 
OPA: 50% Acetonitrile that improved the peak 
shapes of Mupirocin and Fluticasone. For the 
selection of organic constituent of mobile phase, 
acetonitrile was chosen to reduce the longer 
retention time and to attain good peak shape. 
Therefore, final mobile phase composition 
consisting of a mixture of buffer-pH 2.0 (0.1% 
OPA): Acetonitrile. Flow rates between 0.5 
to1.2ml/min were tried. Flow rate of 1ml/min was 
observed to be enough to get all the drugs eluted 
within less than 10min. The column temperature 
was set at 30oC. Optimized method was providing 
good resolution and peak shape for Mupirocin and 
Fluticasone. Under above described experimental 
conditions, all the peaks were well defined and free 
from tailing. The concern of small deliberate 
changes in the mobile phase composition, flow 
rates, and column temperature on results were 
evaluated as a part of testing for methods 
robustness. 
Method development was done by changing mobile 
phase ratios, buffers etc. Following are the 
chromatograms of the trails performed: 
 
 
Fig 3: Optimized Chromatogram 
 
System Suitability:  
For all of them, the peak symmetries were  <1.5 
and the theoretical plates numbers were >2000 and 
%RSD of areas of six standard injections of 
Mupirocin and Fluticasone were less than 2. These 
values are within the acceptable range of United 
States pharmacopoeia definition and the 
chromatographic conditions. The results obtained 
are shown in  (Table 1 and Fig. 4). All the system 
suitability parameters were within the range and 
satisfactory as per ICH guidelines. 
 
Table 1: System suitability parameters for Mupirocin and Fluticasone 
 
S no Mupirocin Fluticasone 
 
Inj 
 
RT(min) 
 
USP Plate 
Count 
 
Tailing 
 
RT(min) 
 
USP Plate 
Count 
 
Tailing 
1 2.141 6364 1.25 2.765 7494 1.28 
2 2.146 6312 1.11 2.767 7944 1.27 
3 2.146 6305 1.15 2.770 7138 1.28 
4 2.147 6713 1.16 2.771 7862 1.28 
5 2.148 6846 1.16 2.780 7801 1.30 
6 2.153 6912 1.18 2.782 7542 1.28 
 
Fig 4: System suitability Chromatogram 
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Method Validation: 
Specificity: 
 Retention times of Mupirocin and Fluticasone 
were 2.146 min and 2.770 min respectively. We did 
not found and interfering peaks in blank and 
placebo at retention times of these drugs in this 
method. So this method was said to be specific The 
specificity of the method was evaluated by 
assessing interference from excipients in the 
pharmaceutical dosage form prepared as a placebo 
solution. Optimized Chromatogram of Mupirocin 
and Fluticasone is shown in Fig. 5 clearly shows 
the ability of the method to assess the analyte in the 
presence of other excipients. 
 
Linearity:   
Six linear concentrations of Mupirocin (75-
450µg/ml) and Fluticasone (1.25-7.5µg/ml) were 
injected in a duplicate manner. Average areas were 
mentioned above and linearity equations obtained 
for Mupirocin was y = 10256.x + 82433 and of 
Fluticasone was y = 24529x + 3330 Correlation 
coefficient obtained was 0.999 for the two drugs as 
shown in Table 2 and Figure 6,7. 
 
 
Fig 5: Typical Chromatogram 
 
Table 2:  Linearity table for Mupirocin and Fluticasone. 
 
 
Mupirocin 
 
Fluticasone 
Conc   (μg/mL) Peak area Conc   (μg/mL) Peak area 
0 0 0 0 
75 901735 1.25 36678 
150 1631619 2.5 66491 
225 2445171 3.75 95852 
300 3179093 5 124779 
375 3923795 6.25 156626 
450 4648550 7.5 186781 
 
         
Fig No. 6: Calibration curve of Mupirocin             Fig No. 7: Calibration curve of Fluticasone 
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Precision:  
System Precision:  
From a single volumetric flask of working standard 
solution six injections were given and the obtained 
areas were mentioned above. Average area, 
standard deviation and % RSD were calculated for 
two drugs.% RSD obtained as 0.8%and 1.0% 
respectively for Mupirocin and Fluticasone as in 
Table 3 .As the limit of Precision was less than “2” 
the system precision was passed in this method. 
 
Repeatability: 
Multiple sampling from a sample stock solution 
was done and six working sample solutions of same 
concentrations were prepared, each injection from 
each working sample solution was given and 
obtained areas were mentioned in the above table. 
Average area, standard deviation and % RSD were 
calculated for two drugs and obtained as 0.4% and 
0.5% respectively for Mupirocin and Fluticasone 
shown in Table 4. 
  
Table 3: System precision table of Mupirocin and Fluticasone 
 
S. No Area of Mupirocin Area of  Fluticasone 
1. 
3055697 
116240 
2. 
3070668 
116628 
3. 3040090 117554 
4. 
3002213 
114264 
5. 
3039396 
116107 
6. 3020300 115160 
Mean  3038061 115992 
S.D  24415.6 1148.7 
%RSD  
0.8 
1.0 
 
 
Table 4: Repeatability table of Mupirocin and Fluticasone 
S. No 
Area of 
Mupirocin 
Area of 
Fluticasone 
1. 3018441 114459 
2. 3028350 114880 
3. 3005649 115765 
4. 3037981 114442 
5. 
3024676 114813 
6. 3018401 115613 
Mean 3022250 114995 
S.D 10913.1 568.2 
%RSD 
0.4 0.5 
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Intermediate precision (Day_ Day Precision): 
Multiple sampling from a sample stock solution 
was done and six working sample solutions of same 
concentrations were prepared, each injection from 
each working sample solution was given on the 
next day of the sample preparation and obtained 
areas were mentioned in the above table. Average 
area, standard deviation and % RSD were 
calculated for two drugs and obtained as 1.8% and 
1.6% respectively for Mupirocin and Fluticasone 
specified in Table 5.  
Robustness: 
Robustness conditions like Flow minus 
(0.9ml/min), Flow plus (1.1ml/min), mobile phase 
minus (40B:60A), mobile phase plus (50B:50A), 
temperature minus (25°C) and temperature 
plus(35°C) was maintained and samples were 
injected in duplicate manner. System suitability 
parameters were not much affected and all the 
parameters were passed. %RSD was within the 
limit.  
 
 
Table 5: Intermediate precision table of Mupirocin and Fluticasone 
 
S. No Area of  Mupirocin Area of Fluticasone 
1. 
3597970 136520 
2. 3504386 134614 
3. 3484832 139041 
4. 3639840 140166 
5. 
3500182 135033 
6. 3513339 136171 
Mean 3540092 136924 
S.D 63145.3 2219.7 
%RSD 
1.8 1.6 
 
Table 6: Robustness data for Mupirocin and Fluticasone. 
 
S.no   Condition %RSD of Mupirocin %RSD of Fluticasone 
1 Flow rate (-) 0.9ml/min 0.3 0.4 
2 Flow rate (+) 1.1ml/min 1.0 0.8 
3 Mobile phase (-) 45B:55A 0.9 0.6 
4 Mobile phase (+) 55B:45A 0.6 0.7 
5 Temperature (-) 25°C 0.5 0.4 
6 Temperature (+) 35°C 0.3 0.5 
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Accuracy:   
Three levels of Accuracy samples were prepared by 
standard addition method. Triplicate injections 
were given for each level of accuracy and mean 
%Recovery was obtained as 98.75% and 99.42% 
for Mupirocin and Fluticasone respectively shown 
in table 7 and table 8. 
Sensitivity: 
 The LOD of Mupirocin and Fluticasone were 
found to be 0.32 and 0.02 respectively. LOQ values 
of Mupirocin and Fluticasone were found to be 
1.16 and 0.05 respectively as shown in Table 9 and 
Figure 8,9. 
 
Table 7: Accuracy table of Mupirocin 
 
%  Level 
Amount Spiked 
(μg/mL) 
Amount 
recovered 
(μg/mL) % Recovery Mean %Recovery  
50% 
150 147.88 98.59 
98.75% 
150 148.81 99.20 
150 147.32 98.21 
100% 
300 294.57 98.19 
300 295.09 98.36 
300 295.85 98.62 
150% 
450 445.17 98.93 
450 443.82 98.63 
450 449.96 99.99 
 
Table 8: Accuracy table of Fluticasone 
 
%  Level 
Amount Spiked 
(μg/mL) 
Amount 
recovered 
(μg/mL) 
% Recovery Mean %Recovery  
50% 
2.5 2.47 98.88 
99.42% 
2.5 2.51 100.22 
2.5 2.51 100.23 
100% 
5 4.98 99.65 
5 4.95 98.92 
5 4.94 98.75 
150% 
7.5 7.54 100.55 
7.5 7.38 98.35 
7.5 7.44 99.19 
 
Table 9: Sensitivity table of Mupirocin and Fluticasone 
 
Molecule LOD LOQ 
Mupirocin 0.38 1.16 
Fluticasone 0.02 0.05 
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Fig. No. 8: LOD Chromatogram of Standard                Fig.No. 9: LOQ Chromatogram of Standard 
 
Table 12: Degradation Data of Mupirocin 
S.NO Degradation 
Condition 
% Drug Degraded Purity Angle Purity Threshold 
1 Acid 4.86 3.930 4.380 
2 Alkali 2.88 0.485 0.569 
3 Oxidation 1.92 0.151 0.314 
4 Thermal 0.94 0.166 0.337 
5 UV 0.57 0.181 0.328 
6 Water 0.89 0.163 0.314 
 
Table 13: Degradation Data of Fluticasone 
S.NO Degradation 
Condition 
% Drug Degraded Purity Angle Purity Threshold 
1 Acid 4.68 0.904 1.189 
2 Alkali 2.58 0.915 1.203 
3 Oxidation 1.72 0.463 0.671 
4 Thermal 0.53 0.635 0.930 
5 UV 0.50 0.602 0.811 
6 Water 0.70 0.467 0.693 
 
Degradation studies: 
Degradation studies were performed with the 
formulation and the degraded samples were 
injected. Assay of the injected samples was 
calculated and all the samples passed the limits of 
degradation. 
Standards and degraded samples are injected and 
calculated the percentage of drug degraded in 
solution by applying different conditions like acid, 
alkali , oxidative , photolytic , thermal and neutral 
analysis. 
Regarding the pH adjustment in mobile phase for 
the acid and base degradation studies have 
movement in retention time of drugs. But due to 
neutralized acid sample with 2N Base solution and 
base sample with 2N Acid solution there will be no 
change in retention time. 
 
DISCUSSION:  
 From the reported literature review, there were few 
methods established for the determination of 
Mupirocin and Fluticasone in individual and in 
combination with other drugs. It was concluded 
that there was no method reported for the 
simultaneous estimation of the above selected duel 
component dosage form, which promote to pursue 
the present work. The scope and objective of the 
present work is to develop and validate a new 
simple RP-HPLC method for simultaneous 
estimation of Mupirocin and Fluticasone in 
combination dosage form. 
A simple, accurate, precise method was developed 
for the simultaneous estimation of the Mupirocin 
and Fluticasone in ointment dosage form. The 
developed method was found to be simple and have 
short run time which makes the method rapid. The 
robustness of the method was checked in terms of 
varying Flow rate, Column temperature, Mobile 
phase composition. The standard was able to give 
system suitability parameters within limit, which 
indicates that the method is Robust.Several studies 
were reported in the literature for the determination 
of Mupirocin and Fluticasone individually and in 
combination with other drugs like ketoconazole, 
itraconazole, azelastine etc.  
The present work compiled with our initial research 
objectives and demonstrated the applicability of 
HPLC for pharmaceutical analysis of different class 
of drugs namely Mupirocin and Fluticasone. 
 
CONCLUSION: 
In simultaneous RP-HPLC method development, 
Waters HPLC grade with UV detector was used. 
The column used was Discovery C18 (4.6×250mm, 
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5µm) column. Injection volume of 10µL was 
injected and eluted with the mobile phase of mixed 
ortho phosphoric acid and acetonitrile in ration of 
50:50. The flow rate was found to be optimized to 
1ml/min. detection was carried out at 230nm. 
Quantitation was done by external standard method 
with the above mentioned optimized 
chromatographic conditions. This system produced 
symmetric peak shape, good resolution and 
reasonable retention times of Mupirocin and 
Fluticasone at 2.146 and 2.770 minutes 
respectively. 
Mupirocin and Fluticasone showed linearity in the 
range of 75-450µg/ml and 1.25-7.5µg/ml 
respectively. The slope, intercept and correlation 
coefficients were found to be y=10256.x+82433 
and 0.999 respectively for mupirocin and 
y=24529.x+3330 and 0.999 for Fluticasone 
respectively. The amount of drug estimated by the 
proposed method was in good agreement with the 
label claim. 
The % RSD values for precision was found to be 
within the acceptable limits, which revealed that 
the developed method was precise. The developed 
method was found to be robust. The % RSD value 
for percentage recovery of Mupirocin and 
Fluticasone was found to be within the acceptance 
criteria. The results indicate satisfactory accuracy 
of method for simultaneous estimation of the 
Mupirocin and Fluticasone.  
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